'김갑성' 기자의 전체기사
-
Dubai Humanitarian: Powerful New Documentary Reveals Worl…
- 'Coming Together: The Dubai Humanitarian Story' provides behind-the-scenes look inside the heart of global disaster response facility - Launches on World Humanitarian Day, 19 August 2025 - First six months of 2025 saw $48.8m humanitarian aid distributed from Dubai Humanitarian, reflected in its Humanitarian Logistics Databank DUBAI, UAE, Aug. 19, 2025 -- Dubai Humanitarian, the world's largest humanitarian logistics hub, has unveiled a new documentary, Coming Together: The Dubai Humanitarian Story - a gripping behind-the-scenes look at the premier disaster response faci
- 김갑성 기자
- 2025-08-19 17:00
-
HEISHA and Unibird Unveil Groundbreaking Drone Defence Tow…
SHENZHEN, China, Aug. 19, 2025 -- In a strategic collaboration, HEISHA Technology and Unibird have launched the Drone Defence Tower (DDT), an advanced autonomous hangar system integrating one search drone and 32 defensive strike FPV drones. This innovative solution combines HEISHA's expertise in multi-layered autonomous drone docks with Unibird's high-performance FPV drone technology, setting new standards in security and defence applications. DDT video link: The HEISHA drone defense tower is a new milestone for autonomous swarm control with Unibird FPV - YouTube The DDT system
- 김갑성 기자
- 2025-08-19 15:08
-
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately. Nilesh brings over 25 years of leadership experience in the medical technology and life sciences industries, having held senior roles at Johnson & Johnson, GE Healthcare and most recently, West Pharmaceutical Services. At West, he served as Vice President & General Manager, Emerging Markets, where he led commercial, operational, and manufacturing st
- 김갑성 기자
- 2025-08-19 14:14
-
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Th…
SHANGHAI and HONG KONG, Aug. 19, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of CLDN18.2-positive, HER-2 negative unre
- 김갑성 기자
- 2025-08-19 13:26
-
Tigermed Receives MSCI ESG AAA Rating
HANGZHOU, China, Aug. 19, 2025 -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance. MSCI's AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. It reflects Tigermed's consistent efforts to integrate ESG principles into our core operations and strategic decision-making.
- 김갑성 기자
- 2025-08-19 11:15
-
Beyfortus® (nirsevimab) approved in Singapore to protect all…
[ 메디채널 김갑성 기자 ] Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisations in infants by 82.7% (95% CI: 67.8 to 91.5; p<0,0001) through six months (180 days). [2], [3] Administration can be timed during the first year of life to provide protection from birth, or as early as possible. SINGAPORE, Aug. 19, 2025 -- The Health Sciences Authority (HSA)
- 김갑성 기자
- 2025-08-19 11:00
-
RemeGen and Santen Enter into Exclusive Licensing Agreem…
YANTAI, China, Aug. 19, 2025 -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen"). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in South Korea, Thailand, Vietna
- 김갑성 기자
- 2025-08-19 08:00
-
openRxiv names Dr. Tracy Teal first CEO to advance open sc…
[ 메디채널 김갑성 기자 ] Scientist and nonprofit leader who previously led The Carpentries and Dryad to lead the organization that oversees bioRxiv and medRxiv. DAVIS, Calif., Aug. 19, 2025 -- openRxiv announced today that after an extensive international search, its Board of Directors has appointed Dr. Tracy Teal as the organization's inaugural CEO. Dr. Teal has served as interim COO of openRxiv since its launch as an independent non-profit in March of this year, playing a central role in launching the organization and establishing its stewardship of bioRxiv and medRxiv, two of the world's m
- 김갑성 기자
- 2025-08-19 00:00
-
Ansell Receives Frost & Sullivan's 2025 Global Sustainable Hos…
[ 메디채널 김갑성 기자 ] Ansell is recognised for its leadership in hospital supply sustainability, visionary innovation, and customer impact on a global scale. SAN ANTONIO, Aug. 18, 2025 -- Frost & Sullivan, a leader in the information and growth advisory industry, has awarded the title of "2025 Global Sustainable Hospital Supplies Company of the Year" to Ansell, a global provider of safety solutions. Recognised for its outstanding achievements in innovation and customer impact, Ansell is focused on driving sustainable innovation by using fewer or safer materials and continuous
- 김갑성 기자
- 2025-08-18 22:00
-
Aon Announces Strategic Investment in eMed to Scale GLP-1…
[ 메디채널 김갑성 기자 ] Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings DUBLIN, Aug. 18, 2025 -- Aon plc (NYSE: AON), a leading global professional services firm, today announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership will enhance employer sponsored access to GLP-1 therapies and scale solutions for obesity. The investment follows the launch earlier this year of Aon's
- 김갑성 기자
- 2025-08-18 21:30
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-22_WED
- Doing the Good Work: SM underscores practical sustainability at industry forum 18:08
- Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience 18:00
- HUYA Inc. to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025 18:00
- 캠브렉스, API 제조 시설 확충과 미국 의약품 공급 회복력 강화 차원에서 1억 2000만 달러 투자 18:00
- ドバイは中東、アフリカ、南アジアを代表する世界金融センターとしての地位を向上 17:59
- 2025년 쇼상 시상식, 과학과 혁신의 22년 전통을 이어가다 17:54
- 2025年ショー賞（The Shaw Prize）授賞式：科学とイノベーションにおける22年の伝統を継承 17:53
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 22일 19시 40분